Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort

Clinical significance of elevated liver transaminases in HIV-infected patients

(2019) Jia Cai et al.   AIDS

Sexualized drug use (‘chemsex’) and high-risk sexual behaviours in HIV-positive men who have sex with men

(2018) EL Pufall et al.   HIV MEDICINE

First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison

(2018) L Taramasso et al.   HIV MEDICINE

EASL Clinical Practice Guidelines: Management of alcohol-related liver disease

(2018) Mark Thursz et al.   JOURNAL OF HEPATOLOGY

Hepatitis A outbreak disproportionately affecting men who have sex with men (MSM) in the European Union and European Economic Area, June 2016 to May 2017

(2018) Patricia Ndumbi et al.   Eurosurveillance

Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?

(2018) Georgia Vourli et al.   AIDS

Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature

(2017) Bo Wang et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Tolerability of integrase inhibitors in a real-life setting

(2017) Judit Peñafiel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project

(2017) Nicola Squillace et al.   PLoS One

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

(2017) Pedro Cahn et al.   Lancet HIV

Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status

(2017) Charitha Gowda et al.   Open Forum Infectious Diseases

Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient

(2017) Erin S. Christensen et al.   Open Forum Infectious Diseases

Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice

(2016) Mark G.J. de Boer et al.   AIDS

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

(2016) C Hoffmann et al.   HIV MEDICINE

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice

(2016) Antonio Di Biagio et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis

(2016) Lucy Platt et al.   LANCET INFECTIOUS DISEASES

Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial

(2016) Nathalie de Castro et al.   AIDS Research and Therapy

Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals

(2015) L. Taramasso et al.   BIOMEDICINE & PHARMACOTHERAPY

Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients

(2015) Giuseppe Lapadula et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

(2014) Jeffrey L. Lennox et al.   ANNALS OF INTERNAL MEDICINE

Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C

(2014) Christopher B Hurt et al.   ANTIVIRAL THERAPY

Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients

(2014) L. Curtis et al.   HIV CLINICAL TRIALS

Liver Enzyme Elevation During Darunavir-Based Antiretroviral Treatment in HIV-1–Infected Patients With or Without Hepatitis C Coinfection: Data from the ICONA Foundation Cohort

(2014) Antonio Di Biagio et al.   HIV CLINICAL TRIALS

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals

(2013) Caroline A. Sabin et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients

(2013) Jürgen K. Rockstroh et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV–hepatitis C virus coinfected patients

(2012) Eugenia Vispo et al.   AIDS

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

(2012) Edwin DeJesus et al.   LANCET

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES

Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression

(2010) David M Iser et al.   AIDS

Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIV‐Infected Persons without Hepatitis B or C Virus Co‐Infection

(2010) Helen Kovari et al.   CLINICAL INFECTIOUS DISEASES

Prevalence and Factors Associated With Liver Test Abnormalities Among Human Immunodeficiency Virus–Infected Persons

(2009) Nancy Crum–Cianflone et al.   Clinical Gastroenterology and Hepatology

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C

(2009) E. Vispo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY